F-1/A: NeuroSense Therapeutics Files Amendment No. 1 to Form F-1 for Resale of Ordinary Shares and Warrants

NeuroSense Therapeutics has filed an amendment to its Form F-1 registration statement, covering the resale of ordinary shares and warrants by selling shareholders.

Summary

• NeuroSense Therapeutics has filed Amendment No. 1 to its Form F-1 registration statement with the SEC.
• The filing pertains to the resale of up to 3,050,964 ordinary shares and 2,980,000 ordinary warrants by selling shareholders.
• These securities were initially issued under a securities purchase agreement dated April 10, 2024, and in a registered direct offering on April 15, 2024.
• The company will not receive any proceeds from the resale of these securities, but will receive proceeds to the extent the Ordinary Warrants are exercised for cash at an exercise price of $1.50 per share.
• NeuroSense is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases like ALS, AD, and PD.
• Their lead candidate, PrimeC, is being evaluated in a Phase IIb clinical trial (PARADIGM) for ALS.
• The company expects to report additional primary ALS-biomarkers endpoint: TDP-43 and Prostagladin2, in the second or third quarter of 2024.
• Following the FDAs recommendation for additional non-clinical data to support long term use of Ciprofloxacin (as PrimeC is intended for long-term administration in treating ALS) a long-term tox study was initiated.
• Results from this study are expected in Q3 towards the initiation of Phase III study in the US.
• The company plans to have an End of Phase 2 Meeting with the FDA and EMA in the second or third quarter of 2024 and to commence a pivotal clinical trial for PrimeC in ALS treatment by the end of the year.
• The company is an emerging growth company and a foreign private issuer, which allows it to comply with reduced public company reporting requirements.
• The company's ordinary shares and warrants are listed on the Nasdaq Capital Market under the symbols NRSN and NRSNW.
• Investing in the company's securities is highly speculative and involves a high degree of risk.

Sentiment

Score: 6

Explanation: The document contains both positive and negative elements. The positive data from the PARADIGM trial and the FDA endorsement of the CMC development plan are encouraging. However, the company's financial situation, the risks associated with investing in its securities, and the potential for delisting are concerning.

Positives

• PrimeC has received orphan drug designation for ALS treatment from both the FDA and EMA.
• The EMA has granted PrimeC SME status, offering potential benefits leading up to and following drug regulatory approval.
• The company met the primary safety and tolerability endpoints and achieved secondary clinical efficacy endpoints in the top-line results of its 6-month double-blind phase of PARADIGM.
• New positive data analysis from PARADIGM clinical trial demonstrating statistically significant slowing of disease progression in high-risk ALS patients.
• The FDA endorsed the company's proposed CMC development plan for PrimeC.
• The company has a strong patent estate, including patents expiring in 2038.
• The company has a management team with extensive experience in the pharmaceutical industry, particularly in ALS research and clinical trials.

Negatives

• Investing in the company's securities is highly speculative and involves a high degree of risk.
• The company has a limited operating history and a history of incurring significant losses and negative cash flows.
• The company is dependent on the success of its lead product candidate, PrimeC.
• The company has limited experience in conducting clinical trials and relies on clinical research organizations.
• The company's ordinary shares may be delisted from the NASDAQ Capital Market if it fails to maintain compliance with continued listing requirements.
• The company needs substantial additional financing to achieve its goals.
• The company's independent auditor included an explanatory paragraph in its report stating that the company's recurring losses and expectation to incur significant additional losses raise substantial doubt about its ability to continue as a going concern.

Risks

• Failure to maintain compliance with Nasdaq's continued listing requirements could result in delisting.
• The sale of a substantial amount of ordinary shares in the public market could adversely affect the prevailing market price.
• The price of the company's ordinary shares may be volatile.
• There is no guarantee that the Ordinary Warrants will be in the money, and they may expire worthless.
• Conditions in Israel, including the recent conflict, may affect the company's operations.
• The company's commercial insurance does not cover losses that may occur as a result of an event associated with the security situation in the Middle East.
• Political conditions within Israel may affect the company's operations.

Future Outlook

The company plans to have an End of Phase 2 Meeting with the FDA and EMA in the second or third quarter of 2024 and to commence a pivotal clinical trial for PrimeC in ALS treatment by the end of the year. The company expects to report additional primary ALS-biomarkers endpoint: TDP-43 and Prostagladin2, in the second or third quarter of 2024. Following the FDAs recommendation for additional non-clinical data to support long term use of Ciprofloxacin (as PrimeC is intended for long-term administration in treating ALS) a long-term tox study was initiated. Results from this study are expected in Q3 towards the initiation of Phase III study in the US.

Industry Context

The company operates in the biotechnology industry, specifically focusing on neurodegenerative diseases, which represents a significant unmet medical need. The average annual cost of ALS alone is $180,000 per patient, and its estimated annual burden on the U.S. healthcare system is greater than $1 billion.

Comparison to Industry Standards

• The document does not contain enough information to make a detailed comparison to industry standards.
• However, the company's focus on neurodegenerative diseases aligns with a broader industry trend of developing treatments for these conditions.
• Many companies are developing treatments for ALS, AD, and PD, including Biogen, Amylyx Pharmaceuticals, and Denali Therapeutics.
• The company's approach of using a combined therapeutic approach to target multiple disease-related pathways is also consistent with industry trends.

Stakeholder Impact

• Shareholders may be impacted by the potential for dilution and volatility in the share price.
• Employees may be impacted by the company's financial situation and the potential for disruptions due to the situation in Israel.
• Patients with neurodegenerative diseases may benefit from the company's development of new treatments.

Next Steps

• Report on additional primary ALS-biomarkers endpoint: TDP-43 and Prostagladin2, in the second or third quarter of 2024.
• Results from long-term tox study are expected in Q3 towards the initiation of Phase III study in the US.
• Have an End of Phase 2 Meeting with the FDA and EMA in the second or third quarter of 2024.
• Commence a pivotal clinical trial for PrimeC in ALS treatment by the end of the year.

Key Dates

Keywords

NeuroSense Therapeutics, PrimeC, ALS, Ordinary Shares, Warrants, Resale, Clinical Trial, FDA, Emerging Growth Company, Neurodegenerative Diseases